Holdings
Rhenman & Partners Asset Management AB
As of Sep 30, 2026, Rhenman & Partners Asset Management AB reported 87 positions worth US$800M. Largest: Iovance Biotherapeutics, Inc., Merck & Company, Inc. and UnitedHealth Group Incorporated. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Iovance Biotherapeutics, Inc. | 2.5M | US$37.1M | +797K | Sep 30, 2026 |
| Merck & Company, Inc. | 207K | US$30.1M | −6,600 | Sep 30, 2026 |
| UnitedHealth Group Incorporated | 71,400 | US$26.2M | −22,200 | Sep 30, 2026 |
| Vertex Pharmaceuticals Incorporated | 48,935 | US$25.6M | +18,250 | Sep 30, 2026 |
| Gilead Sciences, Inc. | 159K | US$23.7M | −19,200 | Sep 30, 2026 |
| Edwards Lifesciences Corporation | 273K | US$23.6M | +13,000 | Sep 30, 2026 |
| BioMarin Pharmaceutical Inc. | 387K | US$23.2M | +96,400 | Sep 30, 2026 |
| Biogen Inc. | 97,050 | US$21.9M | +2,200 | Sep 30, 2026 |
| Eli Lilly and Company | 18,875 | US$21.8M | −3,440 | Sep 30, 2026 |
| Insmed Incorporated | 187K | US$21.4M | +35,120 | Sep 30, 2026 |